Influenza cases surge in PR as COVID-19 transmission remains high


By THE STAR STAFF
Influenza cases in Puerto Rico have risen sharply in recent weeks, although the virus remains below the island’s epidemic threshold, according to the latest epidemiological surveillance data released Tuesday by Health Secretary Víctor Ramos Otero.
The island Department of Health reported 3,959 new influenza cases during the most recent reporting period, bringing the cumulative total for the 2026-2027 flu season to 23,411 cases. Nearly 80% of laboratory-confirmed cases have been identified as Influenza A.
Despite the increase, Ramos emphasized that influenza activity remains below epidemic levels. Health officials continue to closely monitor the spread of respiratory illnesses, including COVID-19 and respiratory syncytial virus (RSV), to guide vaccination campaigns and prevention efforts.
The highest weekly incidence of influenza was recorded among children ages 4 and younger, with 559 reported cases. The Caguas health region has reported the highest cumulative number of flu cases, totaling 4,853 so far this season.
Health authorities also reported 23 influenza outbreaks in educational institutions across the island, including eight in Ponce, six in Arecibo, three each in the Metro and Fajardo regions, and one each in Bayamón, Caguas and Mayagüez.
The flu hospitalization rate currently stands at 5%, while 33 influenza-related deaths have been recorded during the season. Three deaths were reported during the latest week, and no additional fatalities were under investigation at the time of the report. Meanwhile, influenza vaccination efforts have resulted in 314,546 doses administered across Puerto Rico.
COVID-19 activity, however, continues to show elevated transmission levels. The department reported 2,105 new weekly COVID-19 cases, up from 1,968 the previous week.
Children ages 0 to 9 are experiencing the highest infection rate, at 142.4 cases per 100,000 residents, while the Caguas region again reported the highest regional incidence, with 88.35 cases per 100,000 residents.
Despite the increase in infections, hospitalizations have remained relatively stable, with 45 patients currently hospitalized due to the virus. Puerto Rico has recorded 94 COVID-19-related deaths so far in 2026. Health officials noted that 2025 ended with 285 deaths, the lowest annual total since the pandemic began.
RSV activity remains significantly lower than flu and COVID-19, with 63 new cases reported during the latest surveillance period and 1,438 cases documented so far this year.
The virus continues to disproportionately affect young children and older adults. Nearly half of all RSV cases, 47.5%, have occurred among children ages 1 to 4, while 34.2% have been reported in infants younger than one year. Adults over age 65 account for 8% of cases.
RSV has resulted in 623 hospitalizations this year and one confirmed death.
Meanwhile, dengue fever remains under control and below epidemic levels, according to the Department of Health. Officials reported six new dengue cases, bringing the total number of infections in 2026 to 974. Most cases have been concentrated in the Caguas health region.
Four dengue-related deaths have been confirmed this year, while two additional fatalities remain under preliminary investigation.
“The Department of Health maintains continuous epidemiological surveillance of the principal respiratory diseases, including influenza, COVID-19 and RSV,” Ramos said. “This allows us to understand what is circulating, where transmission is occurring, who is being affected and how severe the impact is. With that information, we can anticipate risks, target prevention and vaccination efforts and respond more effectively to protect public health.”
Separately, the Puerto Rico Community Pharmacy Association and the Puerto Rico Pharmacists Association announced an educational seminar on the dispensing of controlled substances. The event, scheduled for Nov. 18 at the Puerto Rico Pharmacists Association headquarters, will provide updates on prescribing requirements, countersignatures and the use of SCC 42 forms. Representatives from the Auxiliary Secretariat for Public Health Regulation, or SARSP by its initials in Spanish; the U.S. Drug Enforcement Administration; Mental Health and Anti-Addiction Services Administration; and Health Insurance Administration are expected to participate and answer questions from pharmacists.



